Doctor Anthony Hammond

Advancing Medical Knowledge through Research and Innovation.

Publications By and Featuring Dr Hammond

Rheumatologist in Harley Street, West London and St Helier, Jersey.

Dr. Anthony Hammond has a recognised career in Rheumatology and pain management, which contributes extensively to medical literature. His research spans various aspects of rheumatological conditions and interventional spinal pain treatments, reflecting his dedication to advancing medical knowledge and patient care.

Dr. Hammond’s work has been published in numerous journals, showcasing his commitment to improving treatment outcomes and exploring innovative therapeutic approaches.

From early adopting techniques in interventional back pain treatment to investigating the efficacy of biologic therapies, Dr. Hammond’s publications highlight his expertise and influence in the field. His collaborative research efforts with renowned experts worldwide underline the importance of interdisciplinary approaches in tackling complex medical challenges.

This comprehensive list of publications is a testament to Dr. Hammond’s relentless pursuit of excellence in medical research and patient care.

  1. Treatment of Discogenic Back Pain and Sciatica in daily practice: Report of 100 Sequential Cases of Interventional Back Pain Treatment with DISC-FX. A Hammond MD FRCP, C Hess, and C Oram. Pain News l September 2019 Vol 17 No 3

  2. EQ 5-D As a suitable assessment of quality of Life after Epiduroscopy. Multicentre randomised double-blinded pilot study.  Griger, M et al  (in preparation)

  3. Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate. Chandrupatla DMSH, Molthoff CFM, Ritesma IGR, Vos, R, Elsof E, Matsutama T, Low PS, Musters RJP, Hammond A, Windhorst AD, Lamertsma AA, van der Laken CJ, Braands R, Jansen G.

  4. Mini-micro discectomy by DISC-FX appears effective for chronic back and leg pain in daily clinical practice.    Abstract No:  WCMISST17-1024    For oral presentation at WCMISST Paris, May 2017.

  5. Modic Antibiotic Spinal Therapy (MAST).  Early experience in the use of antibiotics in Modic-related back pain (MRBP).  A case report and prospective, open-label, observational study. JoOPM. 2016. 1(5). 3-12.

  6. Rheumatoid Arthritis Patients With Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-term Response When Switched to SC MTX. Accepted as poster for ACR, November 2014.

  7. Access to the Next Wave of Biologic Therapies (Abatacept and Tocilizumab) for the Treatment of Rheumatoid Arthritis in England and Wales: Addressing Difficulties with the Current NICE Guidance (MTA195 and TA198). Yee Chiu, Andrew Ostor, Anthony Hammond, Katharina Sokoll, Marina Anderson, Maya Buch, Michael R Ehrenstein, Patrick Gordon, Sophia Steer, Ian N Bruce. Submitted. Clinical rheumatology

  8. Rheumatoid Arthritis Patients With Inadequate Response to Oral Methotrexate Maintain Satisfactory Disease Control and Durable Long-term Response When Switched to Subcutaneous.  Hammond, A , Bately B.  Eular 2014  poster

  9. Hylastan versus Steroid for Knee Osteoarthritis: Double-blind Randomized Trial. Lawrence Housman MD1, Nebojsa Skrepnik MD, PhD1, Nathan Wei MD, FACP, FACR2, Thomas J Schnitzer MD, PhD3, David Waddell MD4, Charles Birbara MD5, Hasan Tahir BSc, MBBS, FRCP6, Nigel Arden MBBS, FRCP, MSc, MD7, Anthony Hammond MD, FRCP8, Phillippe Goupille MD9, Bernd-Jan Sanson MD, PhD10, Francois Bailleul MD10, Clare Elkins MS11, Thierry Conrozier MD.  Knee Surgery Sports Traumatology Arthroscopy.  Published online 15th Feb 2013. DOI 10.1007/s00167-013-2438-7

  10. Subcutaneous Methotrexate is More Efficacious and Better Tolerated Than Oral Methotrexate: The Experience of a Large Group of Patients in the Rheumatology Department of a District General Hospital A. Liakos ,* , M. Batley , T. Hammond, A. Saha , P. Shrestha, A. Keough. Ann Rheum Dis 2012;71 (Suppl3):672

  11. The Impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Campbell RCJ, Bately M, Hammond A, Ibrahim F, Kingsley G, Scott D. In submission 2011, Clinical Rheumatology.

  12. The efficacy of Infliximab in sciatica induced by disc herniations located at L3/4 or L4/5: A small scale randomised controlled trial.  Karpinnen J, Kothonen T, Hammond A, Bowman C, Malmivaara A, Veeger N, Sdeitsalo S and Hurri H. 2009 The Open Spine Journal. I, 9-13

  13. Use of Parenteral Methotrexate significantly reduces the need for biologic therapy. Rheumatology 2007: 46 (1):i25Use of Parenteral Methotrexate significantly reduces the need for biologic therapy (letter). Rheumatology. 47(2):222, 2008 Feb.

  14. Strict adherence to BASDAI score may mislead the treatment decisions in patients with Ankylosing spondylitis. Arthritis Rheum September 2007, Volume 56.

  15. Abatacept (ABA) provides sustained clinical benefit through 3 years in Rheumatoid Arthritis (RA) in patients (PTs) with inadequate responses to Methotrexate (MTX). Hammond A, Emery P,Aranda R, Becker J P, Zhou Y, Dougados M and Westhovens R. BSR 2007 Final abstract number: 53

  16. Using the health Assessment Questionnaire to estimate preference-based single indices in patients with Rheumatoid Arthritis. Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond A and Brazier J. 2007 Arthritis Care and research (manuscript ref ACR-06-0117) NB provenance of final publication uncertain.

  17. The treatment of disc herniation-induced sciatica with Infliximab. One-year follow-up results of FIRST II, a randomized controlled trial. Korhonen T, KarpinnenJ, Paimela L, Malmivaara A,Lindgren K-A, Bowman C, Hammond A, Kirkham B, Jarvinen S, Niinimaki J, Veeger N, Haapea M, Torkki M, Tervonene O, Seitsalo S and Hurri H. 2006. Spine 31: 2759-66.

  18. Bansback N, Brennan A, Reynolds A, Conway P and Hammond T. 2001 In Rheumatoid arthritis (RA) Utility should be Calculated from EQ-5D Rather that SF-36 due to Floor  Effects. Arthritis and Rheumatism, (S) abstract 209 ACR 2001.

  19. Hammond A and Jeganathan N. 2001. Experience of anti-TNF treatment with Infliximab (Remicade) and Methotrexate in routine clinical practice over 40 weeks. Rheumatology 40: 149 (S1)

  20. Hammond A and Jeganathan N. 2001. Hylan GF-20 in avoidance of knee surgery. Rheumatology 40: 299 (S1).

  21. Peterson PL, Steer S, DeLord D, and Hammond A. 2001. Treatment of refractory orbital
    myositis with Infliximab (Remicade) a case report. Rheumatology 40: 346 (S1)

  22. Monaghan J, Hammond A, Rodway A, Conry B and MacFarlane D. 2001. Identifying Patients at risk of Osteoporosis in General Practice. Osteoporosis International 12: S40 (S1)

  23. Steer S, Monaghan J and Hammond A. 1999. Maidstone Osteoporosis Case Ascertainment
    Study: Discovering Unmet Need. 1999. Annals Rheum Diseases. 242. (S)

  24. Donnelly, S., J.T. Bourne, D.A. Levinson, D.V.Doyle, and A Hammond. 1993. Grand Rounds in Rheumatology: Amyloid arthritis associated with IgM kappa lymphoplamacytoid lymphoma. British Journal of Rheumatology. 32: 1004 –1007

  25. Spector TD. Woodward L. Hall GM. Hammond A. Williams A. Butler MG. James IT. Hart
    DJ. Thompson PW. Scott DL. 1992. Keratan sulphate in rheumatoid arthritis, osteoarthritis, and inflammatory diseases. Annals of the Rheumatic Diseases.51(10):1134-7.

  26. Hammond, A., W. Ollier, and MJ. Walport. 1992. Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B. Clin. Exp. Immunol. 88:163-8.

  27. Hammond, A., AC. Rudge, S. Loizou, SJ. Bowcock, and MJ. Walport. 1989. Reduced numbers of CR1 on erythrocytes from patients with SLE and the antiphospholipid syndrome are associated with increased levels of anticardiolipin antibodies. Arthritis and Rheumatism. 32: 259-264.

  28. Walport, M.J., Hammond, A, Davies, K.A.A., Moldenuaer, F. 1989. Complement receptor
    type-1 and SLE. In: Proceedings of the Second International Conference on SLE.
    Professional Postgraduate Services, Tokyo, 52-55.

  29. Hammond A, Loizou S, Cofiner C, Walport MJ. 1990. Anticardiolipin antibodies (ACA) may be a common anti-erythrocyte autoantibody. Clinical and Experimental Rheumatology. 8: 32B (S).

  30. Hammond A, Rudge AC, Loizou S, Bowcock SJ, Walport MJ. 1988. Anticardiolipin antibodies (ACA), complement, and erythrocyte complement receptor type 1 (CR1). British Journal of Rheumatology. 27:2 151 (S).

  31. Hammond A and Walport MJ. 1988. C4A and C4B deposition on red cells from patients with SLE and normal controls. British Journal of Rheumatology. 27:2 40 (S).

  32. Hammond A, Denton A, Ensor A, Scott DL, Doyle DV. 1992. Which clinical measurements are suitable to follow-up ankylosing spondylitis? British Journal of Rheumatology. 31:2 72 (S).

  33. Hammond A and Doyle DV. 1992. Computers in medical audit: experience with the NE Thames Clinical Information System (CIS). British Journal of Rheumatology. 31:2 146 (S).

  34. Woodward L, Spector TD, Hammond A, Hall GM, Williams A, Doyle DV, Scott D.L. 1991.
    Keratan Sulphate and the acute phase response. British Journal of Rheumatology.30:2 236 (S).

  35. Doyle DV and Hammond A. 1990. Rheumatology Clinical Referral Audit and General Practitioner Education Planning. British Journal of Rheumatology. 29:2 169 (S)

  36. Johnston, SRD, A. Hammond, L. Griffiths, R. Greenwood, and CRA. Clarke. 1989. Subarachnoid haemorrhage – can we do better? Journal of the Royal Society of Medicine. 82:721-724.

  37. Pozniak, A, and A. Hammond. 1983. A report on the use of trans-oesophageal pacing in a case of hypothermia. Brit Med J. 289: 1315.